USPTO serial 79362721
LEEZOVI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 14, 2023
- Examiner
- LEIPZIG, MARC J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with LEEZOVI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Michelle J. Levin
Michelle J. Levin Leason Ellis LLP1 Barker Ave., 5th FloorWhite Plains, NY 10601UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biological and biochemical products for industrial, scientific, and diagnostic purposes, namely, biological tissue cultures, diagnostic preparations for scientific use; Chemical preparations for use in separation processes for biological materials; reagents for scientific and research use, namely, reagents for cell separation, labeling reagents, and reagents for the preparation of media, all for commercial and scientific purposes and for the use in medical laboratories; chemical reagents, other than for medical or veterinary purposes with magnetic beads; chemical antibody reagents, other than for medical or veterinary purposes; buffer solutions for scientific purposes in analytical chemistry and chemical reagents, for non-medical purposes, for use with laboratory instruments, especially separation instruments, chemical analysis instruments, reactors and imaging instruments; reagents, other than for medical or veterinary purposes, for processing of biological material, especially tissue, bone marrow, cells, blood; diagnostic reagents and preparations for scientific purposes and for use in medical laboratories; cell culture media, for in-vivo imaging, all for scientific purposes; chemical reagents for non-medical purposes, namely, for use in biotechnology, in biological treatment processes and in the biotechnology industry | ACTIVE | — |
| 005 | Pharmaceutical preparations for use in treating cancer or autoimmune diseases; veterinary preparations for use in treating cancer or autoimmune diseases in household animals and horses; medicinal preparations for cancer or autoimmune diseases; Reagents and media for medical and veterinary diagnostic purposes; diagnostic reagents for medical use and veterinary diagnostic reagents, namely, reagents containing magnetic beads, antibody reagents and reagents for the processing, separation, isolation, enrichment, depletion, detection, screening, analysis and counting of material, especially of biological materials; Reagents for medical use and clinical medical reagents, namely, reagents for use with medical instruments, especially separation instruments, analysis instruments, reactor and imaging instruments; reagents for the processing of biological material, especially tissue, bone marrow, cells, blood and its components, all for medical or veterinary purposes; Media for bacteriological cultures; diagnostic reagents and preparations for medical and veterinary purposes; contrast agents for in-vivo imaging, all for medical and veterinary purposes; pharmaceutical preparations for cellular therapy | ACTIVE | — |
| 042 | Medical, pharmaceutical and biotechnological laboratory services; medical laboratory services and laboratory research services relating to pharmaceuticals, in particular in connection with the manufacture of cell therapeutic agents, cell compounds, cellular medicines, and featuring the selection, stimulation, and activation of cells, as well as the manufacture of medical and scientific kits and reagents | ACTIVE | — |
| 044 | Medical services, in particular the field of extracorporeal plasma therapy; medical treatment services, namely, medical treatment of cancer or autoimmune diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Miltenyi Biotec B.V. & Co. KG
- Other trademarks owned by Miltenyi Biotec B.V. & Co. KG
- Other trademarks owned by Miltenyi Biotec B.V. & Co. KG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named LEEZOVI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 12, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 21, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 21, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 14, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 14, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 14, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 29, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 29, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 9, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 26, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 26, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 26, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 26, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 24, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 22, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 19, 2023 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Jun 28, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 28, 2023 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jun 28, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 28, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 28, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jun 28, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 24, 2023 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 21, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 21, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 17, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 16, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 16, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 21, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 16, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |